Dyskinesia matters.
animal models
basal ganglia
drug development
pathophysiology
therapy complications
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
23
08
2019
revised:
18
11
2019
accepted:
02
12
2019
pubmed:
25
12
2019
medline:
28
4
2021
entrez:
25
12
2019
Statut:
ppublish
Résumé
Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued. © 2019 International Parkinson and Movement Disorder Society.
Substances chimiques
Antiparkinson Agents
0
Levodopa
46627O600J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
392-396Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Chaudhuri KR, Jenner P, Antonini A. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease? Mov Disord 2019;34(6):816-819.
Manson A, Stirpe P, Schrag A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012;2(3):189-198.
Cenci MA. Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 2014;5:242.
Granderouge. "Dear Prof. Chaudhuri… 2019." https://granderouge.wordpress.com/2019/05/01/dear-mr-chaudhuri/?fbclid=IwAR17AQ-h4ymWNaTtjqtYiS71eOA8QBuOzbS30bVEAfJFn7MP0-pWMJImLsw2019. Accessed on December 12, 2019.
Goubault E, Nguyen HP, Bogard S, et al. Cardinal motor features of Parkinson's disease coexist with peak-dose choreic-type drug-induced dyskinesia. J Parkinsons Dis 2018;8(2):323-331.
Goubault E, Nguyen HP, Bogard S, et al. Remnants of cardinal symptoms of Parkinson's disease, not dyskinesia, are problematic for dyskinetic patients performing activities of daily living. Front Neurol 2019;10:256.
Pahwa R, Isaacson SH, Torres-Russotto D, Nahab FB, Lynch PM, Kotschet KE. Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel. Expert Rev Neurother 2018;18(8):669-680.
Morgante L, Morgante F, Moro E, et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord 2007;13(8):528-531.
Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68(1):18-27.
Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 2014;20(2):142-148.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284(15):1931-1938.
Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50(5 suppl. 5):S17-S25.
de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004;127(Pt 4):888-899.
Cenci MA, Ohlin KE, Odin P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets 2011;10(6):670-684.
Poewe W, Chaudhuri KR, Bergmann L, Antonini A. Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegener Dis Manag 2019;9(1):39-46.
Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014;137(Pt 10):2731-2742.
Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006;99(2):381-392.
Cerri S, Siani F, Blandini F. Investigational drugs in phase I and phase II for levodopa-induced dyskinesias. Expert Opin Inv Drugs 2017;26(7):777-791.
Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009;87(1):1-9.
Nyholm D, Johansson A, Aquilonius SM, Hellquist E, Lennernas H, Askmark H. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin Neuropharmacol 2012;35(1):6-14.
Melgari JM, Salomone G, di Biase L, Marano M, Scrascia F, Di Lazzaro V. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: management inclinical practice. Parkinsonism Relat Disord 2015;21(3):327-328.
Meloni M, Solla P, Mascia MM, Marrosu F, Cannas A. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease. Parkinsonism Relat Disord 2017;37:92-96.
Amanzio M, Palermo S, Zibetti M, et al. Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease. Brain Cogn 2014;90:135-141.
Pietracupa S, Fasano A, Fabbrini G, et al. Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms. Parkinsonism Relat Disord 2013;19(11):1004-1008.
Vitale C, Pellecchia MT, Grossi D, et al. Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci 2001;22(1):105-106.
Sitek EJ, Soltan W, Wieczorek D, Robowski P, Schinwelski M, Slawek J. Assessing self-awareness of dyskinesias in Parkinson's disease through movie materials. Funct Neurol 2011;26(3):121-126.
Palermo S, Lopiano L, Morese R, et al. Role of the cingulate cortex in dyskinesias-reduced-self-awareness: an fMRI study on Parkinson's disease patients. Front Psychol 2018;9:1765.
Delpont B, Lhommee E, Klinger H, et al. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease. Mov Disord 2017;32(11):1566-1573.
Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23(2):75-81.
Antonini A, Fung VS, Boyd JT, et al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord 2016;31(4):530-537.
Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson's disease cohort. Eur J Neurol 2016;23(2):304-312.
Cenci MA, Crossman AR. Animal models of l-dopa-induced dyskinesia in Parkinson's disease. Mov Disord 2018;33(6):889-899.
Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015;132:96-168.
Jourdain VA, Tang CC, Holtbernd F, et al. Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia. JCI Insight 2016;1(15):e86615.
Lerner RP, Francardo V, Fujita K, et al. Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Sci Rep 2017;7(1):16005.
Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. NeuroImage 2012;61(1):228-239.
Boi L, Pisanu A, Greig NH, et al. Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease. Mov Disord 2019;34(12):1818-1830.
Alcacer C, Andreoli L, Sebastianutto I, Jakobsson J, Fieblinger T, Cenci MA. Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. J Clin Invest 2017;127(2):720-734.
Parker JG, Marshall JD, Ahanonu B, et al. Diametric neural ensemble dynamics in parkinsonian and dyskinetic states. Nature 2018;557(7704):177-182.
Ryan MB, Bair-Marshall C, Nelson AB. Aberrant striatal activity in parkinsonism and levodopa-induced dyskinesia. Cell Rep 2018;23(12):3438-3446 e3435.
Fox SH, Brotchie JM. Viewpoint: developing drugs for levodopa-induced dyskinesia in PD: lessons learnt, what does the future hold? Eur J Neurosci 2019;49(3):399-409.
Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain 2015;138(Pt 4):963-973.
Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-186.
Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000;9(1):87-100.
Perez-Lloret S, Negre-Pages L, Damier P, et al. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 2017;24(12):1532-1538.
Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63(12):1756-1760.
Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak FB. Levodopa is a double-edged sword for balance and gait in people with Parkinson's disease. Mov Disord 2015;30(10):1361-1370.
Rascol O, Perez-Lloret S, Damier P, et al. Falls in ambulatory non-demented patients with Parkinson's disease. J Neural Transm (Vienna) 2015;122(10):1447-1455.